825 related articles for article (PubMed ID: 11857039)
1. Adenovirus-mediated CD40 ligand gene-engineered dendritic cells elicit enhanced CD8(+) cytotoxic T-cell activation and antitumor immunity.
Liu Y; Zhang X; Zhang W; Chen Z; Chan T; Ali K; Jia Z; Xiang J
Cancer Gene Ther; 2002 Feb; 9(2):202-8. PubMed ID: 11857039
[TBL] [Abstract][Full Text] [Related]
2. Dendritic cells engineered to express the Flt3 ligand stimulate type I immune response, and induce enhanced cytoxic T and natural killer cell cytotoxicities and antitumor immunity.
Liu Y; Huang H; Chen Z; Zong L; Xiang J
J Gene Med; 2003 Aug; 5(8):668-80. PubMed ID: 12898636
[TBL] [Abstract][Full Text] [Related]
3. Enhanced HER-2/neu-specific antitumor immunity by cotransduction of mouse dendritic cells with two genes encoding HER-2/neu and alpha tumor necrosis factor.
Chen Z; Huang H; Chang T; Carlsen S; Saxena A; Marr R; Xing Z; Xiang J
Cancer Gene Ther; 2002 Sep; 9(9):778-86. PubMed ID: 12189528
[TBL] [Abstract][Full Text] [Related]
4. Lymphotactin gene-modified bone marrow dendritic cells act as more potent adjuvants for peptide delivery to induce specific antitumor immunity.
Cao X; Zhang W; He L; Xie Z; Ma S; Tao Q; Yu Y; Hamada H; Wang J
J Immunol; 1998 Dec; 161(11):6238-44. PubMed ID: 9834111
[TBL] [Abstract][Full Text] [Related]
5. In vivo gene transfer of CD40 ligand into colon cancer cells induces local production of cytokines and chemokines, tumor eradication and protective antitumor immunity.
Sun Y; Peng D; Lecanda J; Schmitz V; Barajas M; Qian C; Prieto J
Gene Ther; 2000 Sep; 7(17):1467-76. PubMed ID: 11001366
[TBL] [Abstract][Full Text] [Related]
6. Concurrent delivery of tumor antigens and activation signals to dendritic cells by irradiated CD40 ligand-transfected tumor cells resulted in efficient activation of specific CD8+ T cells.
Liu KJ; Lu LF; Cheng HT; Hung YM; Shiou SR; Whang-Peng J; Juang SH
Cancer Gene Ther; 2004 Feb; 11(2):135-47. PubMed ID: 14647233
[TBL] [Abstract][Full Text] [Related]
7. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
[TBL] [Abstract][Full Text] [Related]
8. TNF-alpha gene-modified dendritic cells act as more potent adjuvants for peptide delivery to induce specific antitumor immunity in mice.
Zhang W; Yang H; Wang Z; Jim X
Chin Med J (Engl); 2002 Dec; 115(12):1767-71. PubMed ID: 12622920
[TBL] [Abstract][Full Text] [Related]
9. Tumor regression induced by intratumor administration of adenovirus vector expressing CD40 ligand and naive dendritic cells.
Kikuchi T; Miyazawa N; Moore MA; Crystal RG
Cancer Res; 2000 Nov; 60(22):6391-5. PubMed ID: 11103803
[TBL] [Abstract][Full Text] [Related]
10. T-cell-dependent antitumor effects produced by CD40 ligand expressed on mouse lung carcinoma cells are linked with the maturation of dendritic cells and secretion of a variety of cytokines.
Tada Y; O-Wang J; Yu L; Shimozato O; Wang YQ; Takiguchi Y; Tatsumi K; Kuriyama T; Takenaga K; Sakiyama S; Tagawa M
Cancer Gene Ther; 2003 Jun; 10(6):451-6. PubMed ID: 12768190
[TBL] [Abstract][Full Text] [Related]
11. Generation of human dendritic cells that simultaneously secrete IL-12 and have migratory capacity by adenoviral gene transfer of hCD40L in combination with IFN-gamma.
Knippertz I; Hesse A; Schunder T; Kämpgen E; Brenner MK; Schuler G; Steinkasserer A; Nettelbeck DM
J Immunother; 2009 Jun; 32(5):524-38. PubMed ID: 19609245
[TBL] [Abstract][Full Text] [Related]
12. [Enhanced antitumor effects induced by lymphotactin gene-modified dendritic cells after pulsed with tumor antigen peptide].
Zhang W; He L; Cao X
Zhonghua Yi Xue Za Zhi; 1999 Mar; 79(3):170-3. PubMed ID: 11601032
[TBL] [Abstract][Full Text] [Related]
13. CD40 signalling induces IL-10-producing, tolerogenic dendritic cells.
Tuettenberg A; Fondel S; Steinbrink K; Enk AH; Jonuleit H
Exp Dermatol; 2010 Jan; 19(1):44-53. PubMed ID: 19889024
[TBL] [Abstract][Full Text] [Related]
14. In vitro activation of cancer patient-derived dendritic cells by tumor cells genetically modified to express CD154.
Loskog A; Tötterman TH; Böhle A; Brandau S
Cancer Gene Ther; 2002 Oct; 9(10):846-53. PubMed ID: 12224026
[TBL] [Abstract][Full Text] [Related]
15. alpha-fetoprotein and interleukin-18 gene-modified dendritic cells effectively stimulate specific type-1 CD4- and CD8-mediated T-Cell response from hepatocellular carcinoma patients in Vitro.
Cao DY; Yang JY; Dou KF; Ma LY; Teng ZH
Hum Immunol; 2007 May; 68(5):334-41. PubMed ID: 17462500
[TBL] [Abstract][Full Text] [Related]
16. Herpes simplex virus (HSV) amplicon-mediated codelivery of secondary lymphoid tissue chemokine and CD40L results in augmented antitumor activity.
Tolba KA; Bowers WJ; Muller J; Housekneckt V; Giuliano RE; Federoff HJ; Rosenblatt JD
Cancer Res; 2002 Nov; 62(22):6545-51. PubMed ID: 12438249
[TBL] [Abstract][Full Text] [Related]
17. Intratumoral administration of immature dendritic cells following the adenovirus vector encoding CD40 ligand elicits significant regression of established myeloma.
Liu Y; Xia D; Li F; Zheng C; Xiang J
Cancer Gene Ther; 2005 Feb; 12(2):122-32. PubMed ID: 15565183
[TBL] [Abstract][Full Text] [Related]
18. Enhanced antitumor immunity derived from a novel vaccine of fusion hybrid between dendritic and engineered myeloma cells.
Hao S; Bi X; Xu S; Wei Y; Wu X; Guo X; Carlsen S; Xiang J
Exp Oncol; 2004 Dec; 26(4):300-6. PubMed ID: 15627063
[TBL] [Abstract][Full Text] [Related]
19. CD40 cross-linking bypasses the absolute requirement for CD4 T cells during immunization with melanoma antigen gene-modified dendritic cells.
Ribas A; Butterfield LH; Amarnani SN; Dissette VB; Kim D; Meng WS; Miranda GA; Wang HJ; McBride WH; Glaspy JA; Economou JS
Cancer Res; 2001 Dec; 61(24):8787-93. PubMed ID: 11751400
[TBL] [Abstract][Full Text] [Related]
20. Antitumor immunity against bladder cancer induced by ex vivo expression of CD40 ligand gene using retrovirus vector.
Kimura T; Ohashi T; Kikuchi T; Kiyota H; Eto Y; Ohishi Y
Cancer Gene Ther; 2003 Nov; 10(11):833-9. PubMed ID: 14605669
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]